← Browse by Condition
Medical Condition

peripheral t cell lymphoma

Total Trials
11
Recruiting Now
11
Trial Phases
Phase 2, Phase 1, Phase 1, Phase 2
NCT04984837 Phase 2
Recruiting

Study of Lacutamab in Peripheral T-cell Lymphoma

Enrollment
56 pts
Location
Belgium, France, Ger...
Sponsor
The Lymphoma Academic Research...
View Trial →
NCT06914037 Phase 1
Recruiting

A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies

Enrollment
24 pts
Location
China
Sponsor
Tianjin Medical University Can...
View Trial →
NCT05675813 Phase 1, Phase 2
Recruiting

Genotype-guided Treatment in Newly Diagnosed PTCL

Enrollment
264 pts
Location
China
Sponsor
Ruijin Hospital
View Trial →
NCT06131801
Recruiting

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

Enrollment
30 pts
Location
United States
Sponsor
Children's Hospital Medical Ce...
View Trial →
NCT04390737 Phase 1, Phase 2
Recruiting

Evaluate the Safety and Clinical Activity of HH2853

Enrollment
254 pts
Location
United States, China
Sponsor
Haihe Biopharma Co., Ltd.
View Trial →
NCT07356245 Phase 2
Recruiting

Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma

Enrollment
44 pts
Location
United States
Sponsor
Jonathan Brammer
View Trial →
NCT06509945
Recruiting

Allo-PBSCT as the First-line Treatment for Patients With the High-risk PTCL

Enrollment
50 pts
Location
China
Sponsor
Shanghai General Hospital, Sha...
View Trial →
NCT06468267 Phase 2
Recruiting

RIC With Thiotepa Combined With Bu/Flu/Ara-C in Allo-HSCT for Relapsed or Refractory PTCL.

Enrollment
50 pts
Location
China
Sponsor
Xianmin Song, MD
View Trial →
NCT07283822 Phase 2
Recruiting

Amping up With PemJAK

Enrollment
53 pts
Location
United States
Sponsor
Seda S. Tolu
View Trial →
NCT06244368 Phase 2
Recruiting

GVM±R in Patients With Relapsed or Refractory Aggressive NHL.

Enrollment
115 pts
Location
China
Sponsor
Institute of Hematology & Bloo...
View Trial →
NCT07389616 Phase 2, Phase 3
Recruiting

A Clinical Trial of Cidabenamine Plus Azacitidine to Prevent Post-Transplant Progression in High-Risk Peripheral T-Cell Lymphoma

Enrollment
40 pts
Location
China
Sponsor
Shanghai General Hospital, Sha...
View Trial →